Article
Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Jun 2012
List Alan F, Baer Maria R, Steensma David P, Raza Azra, Esposito Jason, Martinez-Lopez Noelia, Paley Carole, Feigert John, Besa Emmanuel
Abstract excerpt
PURPOSE: This 3-year, prospective, multicenter trial assessed the safety and efficacy of deferasirox in low- or intermediate-1-risk myelodysplastic syndrome (MDS). PATIENTS AND METHODS: Eligible patients had serum ferritin ≥ 1,000 μg/L and had received ≥ 20 units of RBCs with ongoing transfusion...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.